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Chronic BDNF simultaneously 
inhibits and unmasks superficial 
dorsal horn neuronal activity
Sascha R. A. Alles1,2,6*, Max A. Odem3,6, Van B. Lu2,4, Ryan M. Cassidy5 & Peter A. Smith2
Brain-derived neurotrophic factor (BDNF) is critically involved in the pathophysiology of chronic pain. 
However, the mechanisms of BDNF action on specific neuronal populations in the spinal superficial 
dorsal horn (SDH) requires further study. We used chronic BDNF treatment (200 ng/ml, 5–6 days) 
of defined-medium, serum-free spinal organotypic cultures to study intracellular calcium  ([Ca2+]i) 
fluctuations. A detailed quantitative analysis of these fluctuations using the Frequency-independent 
biological signal identification (FIBSI) program revealed that BDNF simultaneously depressed activity 
in some SDH neurons while it unmasked a particular subpopulation of ‘silent’ neurons causing them to 
become spontaneously active. Blockade of gap junctions disinhibited a subpopulation of SDH neurons 
and reduced BDNF-induced synchrony in BDNF-treated cultures. BDNF reduced neuronal excitability 
assessed by measuring spontaneous excitatory postsynaptic currents. This was similar to the 
depressive effect of BDNF on the  [Ca2+]i fluctuations. This study reveals novel regulatory mechanisms 
of SDH neuronal excitability in response to BDNF.
Injury to, or disease of, the somatosensory system frequently generates chronic and sometimes intractable neuro-
pathic  pain1, 2. In experimental animals, peripheral nerve damage, such as that generated by chronic constriction 
or section of the sciatic nerve, induces pain-related behaviours that serve as a model for human neuropathic 
 pain3, 4. Seven or more days of sciatic nerve injury promote an enduring increase in the excitability of first order 
primary afferent  neurons5–8. These become chronically active and release a variety of mediators (cytokines, 
chemokines, neuropeptides, ATP and growth factors) that predispose spinal microglia to a more ‘activated’ 
 state9–14. These in turn, release further mediators, including brain derived neurotrophic factor (BDNF) that 
promote a slowly developing, but persistent increase in excitability of second order neurons in the spinal dorsal 
horn. This ‘central sensitization’ is thought to be responsible for the allodynia, hyperalgesia, spontaneous pain 
and causalgia that characterize neuropathic  pain3, 15. Spinal actions of BDNF involve alteration in  Cl- gradients 
such that the normally inhibitory actions of GABA become  excitatory16, 17. There is also increased excitatory 
synaptic drive to putative excitatory  neurons9, 18. This results in an overall increase in excitability as monitored 
by confocal  Ca2+ imaging in organotypic cultures of rat or mouse spinal  cord9, 18–20. Despite this, the long-term 
effects of upregulated BDNF on neuronal plasticity in the superficial dorsal horn (SDH) are not fully understood.
In our previous work, we developed and used a model to study neuropathic pain whereby defined-medium 
spinal organotypic cultures are treated long-term (5–6 days) with BDNF (200 ng/ml)9, 20–23. BDNF treatment is 
administered at day 20 or more after organotypic cultures are established to allow neurons to mature to a more 
‘adult-like’ state. We demonstrated that lamina II neurons in these organotypic cultures are similar to those in 
acute slices from young adult  rats21. We also showed that the changes that occur in spinal organotypic dorsal horn 
neurons ‘mirror’ those observed in dorsal horn neurons from acute slices obtained from chronic constriction 
injury (CCI) rats at peak mechanical hypersensitivity  levels20. Naïve cultures display spontaneous oscillatory 
changes in intracellular  Ca2+ levels  [Ca2+]i and we have previously shown that the amplitude and frequency of 
these changes in  [Ca2+]i are profoundly increased following 5–6 days treatment with  BDNF20.
We used this model and a new Frequency-independent biological signal identification (FIBSI)24 program to 
quantitatively measure the fluctuations of  [Ca2+]i and examine their synchronicity. Unexpectedly, we observed 
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two opposite effects of BDNF that appeared to occur simultaneously. First, BDNF caused an overall decrease 
in fluctuation size. Second, we noticed a particular population of SDH neurons in naïve cultures that did not 
display typical, marked fluctuations of  [Ca2+]i. This population of ‘silent’ neurons was never seen in BDNF-
treated cultures, suggesting that BDNF unmasks these ‘silent’ neurons and causes them to become spontaneously 
active. We next investigated the role of gap junctions in mediating the  [Ca2+]i fluctuations; application of the gap 
junction blocker octanol to chronic BDNF-treated neurons revealed a subpopulation of neurons that generate 
low-frequency, large  [Ca2+]i fluctuations. Further pharmacological experiments indicated the  [Ca2+]i fluctuations 
in active neurons are regulated by diverse mechanisms including voltage-gated calcium and sodium channels 
as well as GABA and NMDA receptors. Finally, we used FIBSI to reanalyze a previous dataset of spontaneous 
excitatory postsynaptic current (sEPSC) recordings from BDNF-treated dorsal horn neurons in order to quali-
tatively compare the effects of BDNF on the sEPSCs and  [Ca2+]i fluctuations in SDH neurons. The depressive 
effects of BDNF on the sEPSCs in delay and tonic-firing SDH neurons were consistent with the effects on the 
 [Ca2+]i fluctuations. This study reveals novel mechanisms of BDNF regulation of dorsal horn excitability, which 
has implications for the study of chronic neuropathic pain physiology.
Results
Chronic BDNF treatment of spinal organotypic cultures simultaneously depresses and 
unmasks  [Ca2+]i fluctuations in superficial dorsal horn neurons. In previous work we identified 
that chronic BDNF treatment (200 ng/ml, 5–6 days) induces  Ca2+ fluctuations compared to naïve  cultures20, 25 
(Supplementary Video 1A, B). In this study, we performed a detailed quantitative analysis of the fluctuations 
in  [Ca2+]i using Fluo-4 AM  Ca2+ imaging and the FIBSI analysis  program24 to further establish the nature of 
BDNF-induced changes in lamina II neurons of the SDH. Refer to Fig. 1A1–A3 for an example of  [Ca2+]i fluc-
tuations detected by the FIBSI program. Inspection of the FIBSI-processed recordings revealed a subset of naïve 
neurons, which were relatively ‘silent’ (Fig.  1B, left; raw recordings in Supplemental Fig.  1) displaying only 
small amplitude fluctuations for the duration of the recording (‘silent’ = 1.7 ± 0.04 AU; naïve = 53.7 ± 1.6 AU; 
BDNF = 25.5 ± 0.7 AU). No ‘silent’ neurons were found in the BDNF treatment group (Fig. 1B, right). Refer to 
Table 1 for detailed statistical information. This stark contrast suggested BDNF may be unmasking, or activating, 
these ‘silent’ neurons. We grouped the fluctuations in the ‘silent’ neurons together for further comparison to the 
fluctuations in the other active naïve neurons and BDNF-treated neurons. Log-transformed fluctuation ampli-
tudes (Fig. 1C) and area under the curve (AUC; Fig. 1D) were larger in the active naïve population and in BDNF 
treated neurons compared to ‘silent’ neurons. Unexpectedly, both measures were significantly decreased in the 
BDNF condition compared to naive. A plausible explanation for this effect was that chronic BDNF induced a 
concomitant enhancement of  [Ca2+]i fluctuations in some neurons and depression in others. Indeed, the effects 
of BDNF on the relative frequencies (%) for the fluctuation amplitudes (amplitudes were normalized to the 
largest fluctuation in each neuron) revealed a biphasic effect; frequencies of the smaller- and larger-amplitude 
fluctuations were greater in the BDNF-treated neurons compared to the naïve and ‘silent’ neurons (Fig. 1E). We 
next compared the mean parameters between neurons in order to control for differences in sampling periods. 
A < 10% maximal fluctuation amplitude cut-off was applied to each neuron to reduce the effects of low-ampli-
tude noise. As expected, nonparametric comparisons indicated that fluctuation amplitude (Fig. 1F) and AUC 
(Fig. 1G) were both greater in the naïve and BDNF-treated neurons compared to the ‘silent’ neurons, but were 
not significantly different between naïve and BDNF-treated neurons. Further analysis of the fluctuation kinetics 
indicated no effect on duration (Fig. 1H), a modest, but significant decrease in rise time (i.e., peak time is more 
negative) compared to the ‘silent’ neurons (Fig. 1I), and no effect on frequency (Fig. 1J).
Octanol, a gap junction blocker, disinhibits a population of superficial dorsal horn neurons in 
BDNF-treated cultures. It has been shown that gap junctions have regulatory control over network activ-
ity in the substantia gelatinosa26–29. Therefore, gap junctions may play a role in regulating the properties of  [Ca2+]i 
across the network, but the response of individual neurons to the chronic BDNF in the culture may be masked by 
the complex responses of the different types of neurons to  BDNF20, 30. To address this and determine the poten-
tial role of gap junctions in mediating the BDNF-induced fluctuations, we recorded  [Ca2+]i from SDH neurons 
exposed to chronic BDNF and then applied a non-specific gap junction blocker octanol at 1 mM for ≥ 3 min. We 
again performed a detailed analysis using the FIBSI program and a < 10% maximal fluctuation amplitude cut-off 
was applied to each neuron. Inspection of the FIBSI-processed recordings revealed octanol disproportionately 
affected some neurons compared to others (i.e., large increases in amplitude and AUC in some neurons vs minor 
decreases in others). Neurons were grouped based on whether the octanol treatment caused a negative (decrease, 
n = 39) or positive (increase, n = 40) fold change in mean fluctuation amplitude compared to the BDNF (control) 
condition (Fig. 2A). Paired analyses indicated blocking gap junctions with octanol decreased the frequency of 
the BDNF-induced fluctuations (Fig. 2B) while increasing their duration (Fig. 2C) only in the neurons that had 
a positive fold change in mean fluctuation amplitude. Fluctuation rise time was also significantly decreased in 
the same group of neurons (Fig. 2D). These data suggest that blocking gap junctions with octanol selectively 
disinhibited the response to chronic BDNF in a subpopulation of SDH neurons.
Chronic BDNF induces synchrony of  [Ca2+]i fluctuations in organotypic cultures, and blocking 
gap junctions reduces BDNF-induced synchrony. Previous work has shown BDNF-treated SDH neu-
rons generate synchronous  [Ca2+]i  fluctuations20. We verified that finding by using the FIBSI-processed record-
ings and comparing the degree of synchrony between neurons imaged together in naïve and BDNF-treated 
cultures. Adjacency matrixes were generated using Pearson r coefficients; the recording of each neuron was 
correlated with every other neuron imaged within the same naïve or BDNF-treated culture using a Pearson cor-
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relation matrix. The adjacency matrixes for the BDNF-treated cultures showed the neurons were more positively 
correlated with Pearson r coefficients closer to 1 (Fig. 3A), suggesting they exhibited more synchronous  [Ca2+]i 
fluctuations than the naïve cultures. Indeed, we observed synchronous spikes in  [Ca2+]i across multiple BDNF-
treated neurons compared to the naïve neurons (Fig. 3B1–B2). Raster plots depicting the  [Ca2+]i fluctuation 
peaks revealed the presence of multiple waves of synchronous activity in BDNF-treated neurons (Fig. 3C1–C2). 
To further confirm this prediction, the mean coefficient for each neuron was calculated (i.e., the mean correla-
tion of each neuron with every other neuron in its respective culture; refer to Fig. 3A for Fisher Z transformation 
steps). Comparison of the mean Pearson r coefficients revealed BDNF-treated neurons were more positively 
correlated with other neurons in the culture than naïve neurons (Fig. 3D). Considering the role gap junctions 
may play in regulating network activity and synchronous activity, this result led us to anticipate that blocking 
gap junctions may reduce BDNF-induced synchrony within the culture. We used the same approach to measure 
synchrony among neurons within the same cultures treated with BDNF prior to application of octanol, and 
then we asked whether blocking gap junctions caused a decrease in the mean Pearson r coefficients. Indeed, 
octanol caused a net decrease in the mean Pearson r coefficient (Fig. 3E1,E2). Closer inspection revealed octanol 
Figure 1.  BDNF-induced fluctuations of  [Ca2+]I in superficial dorsal horn neurons. (A1–A3) Example 
recording  [Ca2+]i fluctuations sampled in a SDH neuron and the processing steps used by the FIBSI event-
detection program. The running median (red line in A1, window =  ~ 5 s) was calculated based on the raw 
amplitude (AU) and time coordinate data, then the peaks below the running median were traced to form a 
reference line (red line in A2), and then the Ramer–Douglas–Peucker algorithm detected waveforms above the 
reference (red x at event peaks). (B) Left: Examples of  [Ca2+]i activity detected by FIBSI in 3 different neurons. 
Right: The proportion of ‘silent’ neurons in the BDNF-treatment condition was significantly reduced compared 
to the naïve condition. Proportions were compared using a Fisher exact test. (C, D) Violin plots of the log-
transformed values for fluctuation amplitude and AUC. Fluctuation amplitudes and AUC were significantly 
increased in naïve and BDNF-treated neurons compared to the ‘silent’ neurons, while both measures in the 
BDNF-treated neurons were significantly reduced compared to naïve. Neurons sampled: ‘silent’ n = 20 (849 
fluctuations), naïve n = 78 (2651 fluctuations), and BDNF n = 57 (1555 fluctuations). Median with quartiles 
shown. Comparisons made using Brown-Forsythe and Welch’s ANOVA tests and Games-Howell post-hoc test. 
(E) Relative frequency (%) of the fluctuations binned by amplitude. Amplitude values were normalized to the 
largest fluctuation in each neuron. (F–G) The mean fluctuation amplitude and AUC in the naïve and BDNF-
treated neurons were significantly increased compared to the ‘silent’ neurons. (H–J) Further analysis revealed 
little to no effect of BDNF on fluctuation duration or frequency, but the fluctuations in ‘silent’ neurons exhibited 
longer rise times. For scatterplots F–J, the fluctuations that were < 10% the maximal fluctuation amplitude in 
each neuron were omitted to reduce the effects of low-amplitude noise. Scatterplots in F–J show the median with 
the interquartile range. All comparisons of medians in F–K were made using Kruskal–Wallis tests and Dunn’s 
post-hoc test. **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Naïve vs BDNF: P < 0.0001
1C
Brown-Forsythe Games-Howell’s multiple comparison test
F(2, 4598) = 3373, P < 0.0001
Silent vs naïve: P < 0.0001; silent vs BDNF: P < 0.0001; naïve vs 
BDNF: P < 0.0001Welch’s ANOVA
W(2, 2892) = 5458, P < 0.0001
1D
Brown-Forsythe Games-Howell’s multiple comparison test
F(2, 4280) = 1737, P < 0.0001
Silent vs naïve: P < 0.0001; silent vs BDNF: P < 0.0001; naïve vs 
BDNF: P < 0.0001Welch’s ANOVA
W(2, 2502) = 2032, P < 0.0001
1F
Kruskal–Wallis test Dunn’s multiple comparison test
KW = 54.23, P < 0.0001 Silent vs naïve: P < 0.0001; silent vs BDNF: P < 0.0001; naïve vs BDNF: P = 0.0939
1G
Kruskal–Wallis test Dunn’s multiple comparison test




KW = 4.507, P = 0.1051
1I
Kruskal–Wallis test Dunn’s multiple comparison test




KW = 2.810, P = 0.2454
2B
Two-way RM ANOVA Sidak’s multiple comparison test
Interaction:  F(1, 77) = 29.27, P < 0.0001, 10.65% total variation
Control vs octanol (Decrease): P = 0.4469; Control vs octanol 
(Increase): P < 0.0001
Group effect:  F(1, 77) = 0.0392, P = 0.8437, 0.028% total variation
Treatment effect:  F(1, 77) = 14.31, P = 0.0003, 5.208% total vari-
ation
Subjects (matching) effect:  F(77, 77) = 1.994, P = 0.0014, 55.89% 
total variation
2C
Two-way RM ANOVA Sidak’s multiple comparison test
Interaction:  F(1, 77) = 13.95, P = 0.0004, 7.126% total variation
Control vs octanol (Decrease): P = 0.9638; Control vs octanol 
(Increase): P < 0.0001
Group effect:  F(1, 77) = 7.287, P = 0.0085, 4.105% total variation
Treatment effect:  F(1, 77) = 11.50, P = 0.0011, 5.875% total vari-
ation
Subjects (matching) effect:  F(77, 77) = 1.102, P = 0.3349, 43.38% 
total variation
2D
Two-way RM ANOVA Sidak’s multiple comparison test
Interaction:  F(1, 77) = 13.63, P = 0.0004, 7.764% total variation
Control vs octanol (Decrease): P = 0.1876; Control vs octanol 
(Increase): P = 0.0013
Group effect:  F(1, 77) = 0.080, P = 0.7780, 0.049% total variation
Treatment effect:  F(1, 77) = 1.725, P = 0.1929, 0.983% total vari-
ation





U = 606.5, P = 0.0010
3E1
Wilcoxon matched-pairs signed rank test
n/a
W = -1373, P < 0.0001
3E2
Two-way RM ANOVA Sidak’s multiple comparison test
Interaction:  F(1, 58) = 37.70, P < 0.0001, 6.086% total variation
Control vs octanol (Decrease): P < 0.0001; Control vs octanol 
(Increase): P = 0.0450
Group effect:  F(1, 58) = 38.23, P < 0.0001, 29.22% total variation
Treatment effect:  F(1, 58) = 83.93, P < 0.0001, 13.55% total vari-
ation
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Control vs 0  Ca2+: Amplitude P > 0.05; Frequency P > 0.05
Control vs  Cd2+: Amplitude P > 0.05; Frequency P > 0.05
Control vs  Ni2+: Amplitude P > 0.05; Frequency P < 0.001
Control vs nitrendipine: Amplitude P > 0.05; Frequency 
P < 0.001
Control vs ω-conotoxin: Amplitude P > 0.05; Frequency 
P < 0.001
Control vs TTX: Amplitude P > 0.05; Frequency P > 0.05
Control vs riluzole: Amplitude P > 0.05; Frequency P < 0.001
Control vs NBQX: Amplitude P > 0.05; Frequency P > 0.05
Control vs D-AP5: Amplitude P < 0.001; Frequency P > 0.05
Control vs kynurenic acid: Amplitude P > 0.05; Frequency 
P > 0.05
Control vs GABA: Amplitude P > 0.05; Frequency P > 0.05
5C2
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 2916) = 311.1, P < 0.0001
Control vs BDNF (Delay): P = 0.4264; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 2862) = 504.2, P < 0.0001
5D2
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 1761) = 419.3, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 2791) = 541.8, P < 0.0001
500
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 2550) = 159.1, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P = 0.0012Welch’s ANOVA
W(3, 2759) = 162.3, P < 0.0001
5F2
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 2027) = 14.5, P < 0.0001
Control vs BDNF (Delay): P = 0.1284; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 2860) = 27.93, P < 0.0001
S1B
Kruskal–Wallis test Dunn’s multiple comparison test
KW = 44.87, P < 0.0001 Silent vs naïve: P < 0.0001; silent vs BDNF: P = 0.0002; naïve vs BDNF: P = 0.0020
S4A2
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 71793) = 1122, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 54420) = 2011, P < 0.0001
S4A4
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 29988) = 851.4, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 18137) = 2294, P < 0.0001
S4B2
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 55836) = 870.5, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 54028) = 850.3, P < 0.0001
S4B4
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 22611) = 438.9, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 17636) = 1298, P < 0.0001
S4C2
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 72912) = 203.0, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 51340) = 169.4, P < 0.0001
S4C4
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 26038) = 26.33, P < 0.0001
Control vs BDNF (Delay): P = 0.0062; Control vs BDNF (Tonic): 
P = 0.6416Welch’s ANOVA
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decreased the mean Pearson r coefficient in 100% (25/25) of the neurons in the group with decreased fluctuation 
amplitudes, while only 63% (22/35) of the neurons in the group with increased fluctuation amplitudes exhibited 
a decreased mean Pearson r coefficient. This suggests that blocking gap junctions may actually increase  [Ca2+]i 
fluctuation synchrony in some neurons.
Figure Test Post-hoc comparisons
S4D2
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 76383) = 171.1, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 51987) = 167.3, P < 0.0001
S4D4
Brown-Forsythe Games-Howell’s multiple comparison test
F(3, 26111) = 62.09, P < 0.0001
Control vs BDNF (Delay): P < 0.0001; Control vs BDNF (Tonic): 
P < 0.0001Welch’s ANOVA
W(3, 16008) = 62.78, P < 0.0001
Table 1.  Detailed results of statistical analysis per figure.
Figure 2.  Effect of gap junction blocker octanol on BDNF-induced  [Ca2+]I fluctuations. (A) Scatterplot 
summarizing the effects of octanol on mean fluctuation amplitude and examples of FIBSI-processed recordings. 
The two bottom recordings show a decrease in fluctuation amplitude and the two top show an increase. (B–D) 
Neurons were sorted based on whether they exhibited a positive or negative fold change in mean fluctuation 
amplitude in response to octanol. Paired analyses showed octanol selectively and significantly decreased the 
mean fluctuation frequency, increased the mean fluctuation duration, and decreased the mean fluctuation rise 
time (i.e., more negative peak time) in the neurons with positive fold changes in mean fluctuation amplitude. 
Control vs octanol paired comparisons for the groups in (B–D) were made using two-way repeated measures 
ANOVAs and Sidak’s post-hoc test. **P < 0.01, ****P < 0.0001.
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Pharmacology of  [Ca2+]i fluctuations in BDNF-treated slices. In order to further characterize the 
properties of the  [Ca2+]i fluctuations, we used pharmacological treatments to block a variety of voltage-gated 
ion channels, glutamate receptors, and GABA receptors. Comparisons between the pharmacologically-treated 
neurons and the BDNF-treated (control) neurons revealed the  [Ca2+]i fluctuation amplitudes (Fig. 4A) and fre-
quency (Fig. 4B) are controlled by diverse mechanisms (example recordings and data available in Supplemental 
Fig. 2). The fluctuations were ablated when extracellular  Ca2+ was removed, when all voltage-gated calcium chan-
nels (VGCCs) were blocked with  Cd2+, when all TTX-sensitive voltage-gated sodium channels (VGSCs) were 
blocked with tetrodotoxin (TTX), when AMPA or kainite glutamate receptors were blocked with CNQX/NBQX, 
and when GABA was applied to the cultures. Interestingly, the fluctuations remained when we blocked T-type 
(with  Ni2+), L-type (with nitrendipine), or N-type (with ω-conotoxin)  Ca2+ channels, although the frequency 
was significantly reduced with no effect on amplitude. Riluzole, which blocks glutamate release and VGSCs, 
only affected the fluctuation frequency but not amplitude. The NMDA blocker D-AP5 was the only blocker 
to significantly reduce fluctuation amplitudes, but it had no effect on frequency. We also noted that applying 
GABA-A blockers bicuculline (10 µM) and strychnine (1 µM) to BDNF-treated slices (Supplementary Fig. 2P) 
abolishes higher frequency smaller amplitude fluctuations, leaving inducing the larger amplitude low frequency 
fluctuations that occur in naive cultures (Supplementary Fig. 2P). These data suggest the BDNF-induced  [Ca2+]i 
fluctuations are controlled by a combination of VGCCs, TTX-sensitive VGSCs, GABA and NMDA receptors.
Figure 3.  Synchrony of [Ca2 +]i fluctuations in BDNF-treated cultures and the effect of octanol. (A) Example 
adjacency matrix constructed from Pearson r coefficients corresponding to the correlation in activity between 
neurons in a naïve or BDNF-treated culture, each with 8 sampled neurons. Steps to calculate the mean Pearson 
r for each neuron within a culture using the Fisher Z transformation are also depicted. (B1,B2) Example 
recordings of asynchronous  [Ca2+]i fluctuations in naïve neurons and synchronous  [Ca2+]i fluctuations in BDNF-
treated neurons. Recordings shown were processed by FIBSI for event detection and each one was normalized 
(0 to 1 scale) before calculation of the adjacency matrix in A. (C1,C2) Raster plots depicting the fluctuation 
peak times detected by FIBSI for the recordings in B1-B2. Red stars in C2 denote the presence of synchronous 
waves of  [Ca2+]i activity. (D) Neurons sampled from BDNF-treated cultures exhibited significantly greater mean 
Pearson r coefficients compared to neurons sampled from naïve cultures. Neurons were imaged from 4 naïve 
cultures and 3 BDNF-treated cultures, each with ≥ 8 neurons imaged. Medians shown with the 95% confidence 
interval. Medians were compared using a Mann–Whitney test. (E1,E2) Treatment with octanol significantly 
decreased the mean Pearson r in neurons sampled from cultures exposed to chronic BDNF, and this treatment 
effect impacted both subsets of neurons binned based on their initial response to octanol. Neurons were imaged 
from 4 cultures. The control vs octanol paired comparison in C1 was made using a Wilcoxon rank sum test. 
Control vs octanol paired comparisons for the groups in C2 were made using a measures two-way repeated 
measures ANOVA and Sidak’s post-hoc test. *P < 0.05, **P < 0.01, ****P < 0.0001.
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Clustering spontaneous excitatory postsynaptic currents (sEPSCs) reveals chronic BDNF 
treatment depresses excitability of delay and tonic-firing superficial dorsal horn neurons, mir-
roring the effect of BDNF on  [Ca2+]i fluctuations. It is well established that BDNF release in the SDH is 
involved in neuropathic  pain10, 16, 17. However, to our knowledge our findings are the first to show chronic BDNF 
treatment unmasks  [Ca2+]i fluctuations in a subpopulation of SDH neurons while depressing activity in others. 
We had previously shown that sEPSCs recorded from SDH neurons are perturbed in BDNF-treated spinal cord 
organotypic  cultures20. It is plausible that the newly discovered unmasked BDNF-induced  [Ca2+]i fluctuations 
underlie changes in network excitability. We decided to readdress the effects of BDNF on network excitabil-
ity by using the FIBSI program to quantitatively analyze a previous subset of sEPSC recordings in delay and 
tonic-firing SDH neurons (example recordings and low-pass filtering/matching methods are available in Sup-
plemental Fig. 3). Inspection of the sEPSC interevent interval data indicated there might be natural clustering 
between single “small” sEPSCs and larger summated sEPSCs. We used partitioning around medoids (a medoid 
is like a centroid, but is restricted to an actual observation in the dataset) to cluster the sEPSCs in each neuron 
based on 3 sEPSC parameters: interevent interval (ms), amplitude (pA), and charge transfer (Q; essentially area 
under the curve). Optimal clustering (k medoids = 3–5 per neuron) identified 3 main clusters of sEPSCs that 
were present in all delay (Fig. 5A1,A2) and tonic (Fig. 5B1,B2) neurons in both control and BDNF treatment 
conditions (clusters named based on amplitude; interevent interval): (1) small; short, (2) small; long, and (3) 
large. Two other clusters were identified (small; mid and medium), but they were not present in all neurons or 
treatment conditions and were not analyzed for this study. We were mainly interested in the effects of BDNF on 
the cluster of large-amplitude sEPSCs in both neuron types (refer to Supplemental Fig. 4 for the “small” sEPSC 
analysis). Chronic BDNF treatment significantly decreased sEPSC amplitudes (Fig. 5C1,C2) and charge transfer 
(Fig. 5D1,D2) in the tonic-firing neurons. We did not observe a significant effect on sEPSC amplitudes in the 
delay neurons, but charge transfer was significantly decreased. The sEPSCs in the BDNF-treated delay neurons 
were narrower (control duration = 83.6 ± 1.2 ms; BDNF duration = 49.9 ± 0.4 ms). The sEPSC interevent intervals 
were significantly shorter in both neuron types (Fig. 5E1,E2), and peak time measurements indicated BDNF 
significantly increased activation of the sEPSCs in the tonic neuron (Fig. 5F1,F2).
Discussion
The present study was undertaken to better understand mechanisms underlying synchronous activity among 
SDH neurons and the influence BDNF may have on network excitability in naïve, uninjured organotypic cul-
tures. Our experiments indicate long-term exposure to BDNF produces a complex set of neuron-dependent 
changes in network excitability in the SDH. First, BDNF causes a concomitant activation of  Ca2+ signaling in a 
subpopulation of ‘silent’ SDH neurons (~ 20% sampled) and depression of  Ca2+ signaling in many others. This 
finding was largely unexpected as we have previously shown chronic BDNF increases the size and frequency of 
 [Ca2+]i  fluctuations20. It is plausible that the presence of the ‘silent’ neurons can greatly influence data analysis 
and interpretation depending on how they are grouped together, or discarded. Another possibility is that reso-
lution differences between the two event-detection programs used (FIBSI in the current study, Mini Analysis 
Software (Synaptosoft, NJ)) in the previous study) could influence analysis of the  [Ca2+]i fluctuations. However, 
the goal of the present study was not to compare/contrast the two programs. The second significant finding was 
Figure 4.  Pharmacology of  [Ca2+]i fluctuations from BDNF-treated cultures. Summary of the effects of various 
pharmacological treatments on the (A) amplitude and (B) frequency of the  [Ca2+]i fluctuations in BDNF-treated 
cultures compared to before drug treatment. Bars show the mean + standard error of the mean. *P < 0.001, paired 
t-test, n = 5–20 cells per condition.
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that gap junction signaling may play a crucial role in regulating BDNF-induced changes in  Ca2+ signaling in the 
SDH. Blockade of gap junctions with octanol unveiled a subpopulation of neurons that respond to BDNF with 
large-amplitude, low-frequency  [Ca2+]i fluctuations. This finding suggests that gap junctions modulate global 
network activity, either by directly or indirectly inhibiting those particular neurons with increased  Ca2+ signaling. 
Indeed, this is supported by the third major finding that BDNF profoundly increases synchrony of the [Ca2 +]i 
fluctuations, and blocking gap junctions with octanol reverses BDNF-induced synchrony.
It is known that delay neurons are mostly excitatory glutamatergic neurons expressing vesicular glutamate 
transporter 2 (VGLUT2) and that tonic neurons are mostly GABA- or glycinergic inhibitory  neurons31. We also 
know from the pioneering studies of Perl and others that tonic neurons mainly possess an islet morphology and 
that delay neurons possess a radial  morphology32. While the physiological correlates of the BDNF-related  [Ca2+]i 
fluctuations are unclear, we do not think they are being driven by delay or tonic-firing neurons in the SDH. Unlike 
our analysis of the  [Ca2+]i fluctuations where we describe the ‘silent’ neurons, we did not observe any unmasking 
effect(s) of BDNF on the sEPSCs in the delay or tonic neurons. All neurons sampled in the control (naïve) condi-
tion generated visually appreciable, large-amplitude sEPSCs. The main depressive effect of BDNF on the sEPSCs 
(refer also to Supplemental Fig. 4) mirrored the main effect of BDNF on comparable properties for the  [Ca2+]i 
fluctuations. A summary of each dataset (Fig. 6, table) shows BDNF reduced the amplitude and area under the 
curve parameters for the  [Ca2+]i fluctuations and large sEPSCs. More nuanced effects were observed for frequency 
(reciprocal of interevent interval) and activation kinetics: BDNF increased the frequency of the large sEPSCs but 
had little to no effect on the frequency of the  [Ca2+]i fluctuations; BDNF increased activation of the large sEP-
SCs in the tonic neurons and had little to no effect on the delay neurons or  [Ca2+]i fluctuations. However, these 
data collectively suggest chronic BDNF may have reduced excitability in the delay and tonic SDH neurons, and 
this may provide a physiological basis for the depressive effect of chronic BDNF on the  [Ca2+]i fluctuations. On 
the contrary, the ‘silent’ neurons are predicted to have responded to chronic BDNF with  [Ca2+]i fluctuations of 
greater amplitude, total area, frequency, and presumably activation. Our working model (Fig. 6, bottom) posits 
that under naïve conditions many delay and tonic SDH neurons in organotypic spinal cord cultures are generally 
Figure 5.  Cluster analysis of spontaneous EPSCs in delay and tonic-firing superficial dorsal horn neurons. 
Three dimensional representations of the sEPSCs in (A1,A2) delay neurons and (B1,B2) tonic neurons plotted 
based on interevent interval (x-axis), amplitude (y-axis), and charge transfer (z-axis). Mapping of the clustering 
results and treatment shown for the total sample of sEPSCs. The sEPSCs in each neuron were clustered 
independently from the other neurons. Optimal partitioning around medoids identified 3 primary clusters 
present in all neurons in both treatment conditions (naming based on amplitude; interevent interval): small; 
short, small; long, and large. Two additional clusters were identified in some neurons, but were not present in all 
neurons in both conditions: small; mid and medium. Neurons sampled: 19 delay (5 control, 14 BDNF); 9 tonic 
(5 control, 4 BDNF). Total number of sEPSCs: 33,206 in delay, control; 108,261 in delay, BDNF; 40,658 in tonic, 
control; 36,521 in tonic, BDNF. The effects of BDNF on sEPSC amplitude, charge transfer (i.e., area under the 
curve), and peak time were assessed for the 3 primary clusters (large cluster shown, refer to Supplemental Fig. 3 
for the two small-amplitude clusters). (C1,C2) Treatment with BDNF significantly decreased sEPSC amplitudes 
in tonic neurons, but a significant effect was not observed in the delay neurons. Cumulative distributions of 
the measured amplitudes shown (left) alongside the means ± standard error of the means (right). (D1,D2) The 
BDNF treatment significantly reduced sEPSC charge transfer measures in both delay and tonic neurons. (E1,E2) 
Interevent intervals for the sEPSCs within the large cluster were significantly decreased in the BDNF-treated 
neurons. (F1, F2) The sEPSC activation kinetics were significantly faster in the BDNF-treated neurons, but no 
significant effect was observed for the sEPSCs in the delay neurons. Large sEPSC cluster sample sizes: delay 
neurons control n = 753, BDNF n = 4539; tonic neurons control n = 2348, BDNF n = 2367. Comparisons between 
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in an active state, with some gap junction coupling with neighboring neurons. Long-term exposure to BDNF 
causes a homeostatic shift that pushes the SDH into a dampened state marked by synchronous, low-level activity 
spread across the network via increased gap junction coupling. This synchronous activity in turn mitigates the 
BDNF-activated ‘silent’ neurons. From our pharmacology experiments (Fig. 4 and Supplementary Fig. 1), we 
also suggest that activity of GABA- and glycinergic inhibitory receptor systems are necessary to support BDNF-
induced  Ca2+ fluctuations. Given the role of GABA and glycine in sensory processing associated with chronic 
 pain33, it is possible that BDNF-induced fluctuations are important for pathophysiology of neuropathic pain.
Several types of oscillatory and/or rhythmic bursting activity have been previously observed in spinal cord 
organotypic  cultures34, 35 and in ex vivo slice  preparations26, 36–38. BDNF has also been shown to induce long 
term potentiation (LTP) in the spinal dorsal  horn39 and is critically involved in mechanisms of synaptic plastic-
ity, which may induce synchronous activity in different pain states. Synchronous activation of groups of spinal 
nociceptive neurons might contribute to the ‘electric shock’-like sensations experienced by some neuropathic 
pain  patients40. We hypothesize that  [Ca2+]i fluctuations leading to synchronous network activity may be attrib-
uted to the “shooting pains” that chronic pain patients may experience. In particular, “shooting pain” is very 
commonly experienced by patients with radicular lower back pain (sciatica) or trigeminal neuralgia. In these 
patients, stimulus movement elicits so-called “traveling waves” in which neural activity sweeps across the body-
part representation in somatosensory  maps41. The mechanisms of this have been attributed in part to  Ca2+ waves 
and gap junctions 41, 42. Therefore, given the properties of the  [Ca2+]i fluctuations we have identified, they would 
make a good candidate for the neural substrate of shooting pain. In a cohort of chemotherapy-induced peripheral 
neuropathy (CIPN) patients, some of whom reported shooting or burning pain in the hands or feet, serum nerve 
growth factor (NGF) levels were much higher compared with patients with painless or absent  CIPN43. Therefore, 
there is a precedent for the correlation of neurotrophic factors related to BDNF to the incidence of shooting 
pain. Indeed it has been shown that NGF regulates the expression of  BDNF44. It is has also been demonstrated 
that BDNF overexpression induces spasticity in rodent models of spinal cord injury, which may also explain the 
effect of BDNF on influencing network excitability in the dorsal  horn45. With regards to the involvement of the 
dorsal horn in shooting pain, it has been shown that dorsal root entry zone lesioning (DREZotomy) success-
fully reduces shooting pain caused by brachial plexus root avulsion (BPRA)46. Also, in one patient with shooting 
pain caused by osteoid osteoma, a partial laminectomy was able to significantly relieve pain  symptoms47. Ideally 
however, more experiments using human ex vivo tissue are needed to determine whether these particular  [Ca2+]i 
fluctuations correlate with shooting pain in patients.
Materials and methods
Ethics. All experimental protocols were approved by the University of Alberta Animal Care and Use Com-
mittee, which is charged with maintaining standards set forth by the Canadian Council on Animal Care.
Figure 6.  Working model summarizing the effects of chronic BDNF on SDH neurons in this study.
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Defined-medium organotypic cultures of spinal cord slices. All procedures complied with the 
guidelines of the Canadian Council for Animal Care and the University of Alberta Health Sciences Laboratory 
Animal Services Welfare Committee. Spinal cords were isolated from embryonic (E13–14) rats and transverse 
slices (300 ± 25 μm) were cultured using the roller-tube  technique20, 22. Since tissue is obtained from embryos, sex 
could not be determined. Serum-free conditions were established after 5 days in vitro. Medium was exchanged 
with freshly prepared medium every 3–4  days. Slices were treated after 15–21  days in  vitro for a period of 
5–6 days with 50–200 ng/ml in serum-free medium as described  previously20. Age-matched, untreated DMOTC 
slices served as controls.
Calcium imaging. Each organotypic slice was incubated for 1  h prior to imaging with the fluorescent 
 Ca2+-indicator dye Fluo-4-AM (Molecular Probes, Invitrogen, Carlsbad, CA, USA). The conditions for incubat-
ing the dye were standardized across different slices to avoid uneven dye loading. After dye loading, the slice was 
transferred to a recording chamber and superfused with external solution containing (in mM): 131 NaCl, 2.5 
KCl, 1.2  NaH2PO4, 1.3  MgSO4, 26  NaHCO3, 25 d-glucose, and 2.5  CaCl2 (20 °C, flow rate 4 ml/min). Regions 
of interest (ROI) corresponding to individual cell bodies of neurons were identified based on morphology and 
size. Changes in  Ca2+-fluorescence intensity evoked by a high  K+ solution (20, 35, or 50 mM, 90 s application) or 
other pharmacological agents, were measured in dorsal horn neurons with a confocal microscope equipped with 
an argon (488 nm) laser and filters (20 × XLUMPlanF1-NA-0.95 objective; Olympus FV300, Markham, Ontario, 
Canada). Full frame images (512 × 512 pixels) in a fixed xy plane were acquired at a scanning time of 0.8–1.08 s/
frame48. In some experiments, images were cropped to accommodate faster scan rates. Selected regions of inter-
est were drawn around distinct cell bodies depicting neurons based on morphology as described  previously49 
and fluorescence intensity traces were generated with FluoView v.4.3 (Olympus).
Electrophysiology. Whole cell patch-clamp recordings were obtained from neurons in organotypic slice 
cultures under infrared differential interference contrast optics. Neurons selected for recording were located 
250–800 μm from the dorsal edge of the cultures in an area presumed to reflect the substantia gelatinosa and up 
to a depth of 100 μm from the surface. Neurons were categorized according to their firing pattern in response 
to depolarizing current commands as tonic, delay, phasic, irregular, or  transient30. Recordings were obtained 
with an NPI SEC-05LX amplifier (ALA Scientific Instruments, Westbury, NY, USA) in bridge balance or in 
discontinuous, single electrode, current or voltage-clamp mode. Neurons were sampled at 2  k  Hz for 180  s 
when measuring sEPSCs. For recording, slices were superfused at room temperature (∼ 22 °C) with 95% O2-5% 
 CO2-saturated aCSF that contained (in mM) 127 NaCl, 2.5 KCl, 1.2  NaH2PO4, 26  NaHCO3, 1.3  MgSO4, 2.5 
 CaCl2, and 25 d-glucose, pH 7.4. Patch pipettes were pulled from thin-walled borosilicate glass (1.5/1.12 mm 
OD/ID; WPI, Sarasota, FL) to 5- to 10-MΩ resistances when filled with an internal solution containing (in mM) 
130 potassium gluconate, 1 MgCl2, 2 CaCl2, 10 HEPES, 10 EGTA, 4 Mg-ATP, and 0.3 Na-GTP, pH 7.2, 290–300 
mosM.
Drugs and chemicals. Unless otherwise stated, all chemicals were from Sigma (St. Louis, MO, USA). 
Fluo-4 AM dye was dissolved in a mixture of dimethyl sulfoxide (DMSO) and 20% pluronic acid (Invitrogen, 
Burlington, Ontario, Canada) to a 0.5 mM stock solution and kept frozen until used. The dye was thawed and 
sonicated thoroughly before incubating with a DMOTC slice. TTX was dissolved in distilled water as a 1 mM 
stock solution and stored at – 20  °C until use. TTX was diluted to a final desired concentration of 1 µM in 
external recording solution on the day of the experiment. Strychnine was prepared in a similar manner to TTX, 
and bicuculline (Tocris, Ballwin, MO, USA) was dissolved in DMSO as a 10 mM stock solution. 6-cyano-7-ni-
troquinoxaline-2,3-dione (CNQX, Tocris), 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione 
(NBQX, Tocris) and N,N,H,-Trimethyl-5-[(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]-1-pentanaminiumbro-
mide hydrobromide (IEM-1460, Tocris) were prepared as 10 mM stocks dissolved in distilled water, and d(-
)-2-Amino-5-phosphonopentanoic acid (d-AP5, Tocris) was prepared as 50 mM stocks dissolved in 30% 1 M 
NaOH. Riluzole was prepared as a 10 mM stock, kyneurinic acid and GABA as 1 M stocks, and nitrendipine as a 
1 mM stock made up in distilled water. These drugs were used at a 1:1000 dilution prepared freshly with external 
recording solution immediately prior to the start of experiments.
Data analysis and statistical testing. Raw time-lapse calcium fluorescence intensity and whole-cell 
voltage-clamp recordings were analyzed using the Frequency-Independent Biological Signal Identification 
(FIBSI)  program24 written using the Anaconda v2019.7.0.0 (Anaconda, Inc, Austin, TX) distribution of Python 
v3.5.2 and the NumPy and matplotlib.pyplot libraries. The FIBSI program incorporates the Ramer-Douglas-
Peucker algorithm to detect significant waveforms against a time-dependent generated reference line using 
the least number of total points to represent said waveform, and provides quantitative measurements for each 
detected waveform. The calcium fluorescence traces were fit using a sliding median with a window size between 
5 and 25 s, and peaks below the sliding median line were traced together to form the reference line. The voltage-
clamp traces were fit using a sliding median with a window of 50 ms, and peaks above the sliding median were 
traced together to form the reference line. A custom Python script was used to match sEPSCs detected in filtered 
voltage-clamp recordings with the unfiltered recordings. The detected sEPSCs for each neuron were clustered 
based on their amplitude, charge transfer, and interevent interval using the partitioning around medoids func-
tion (default settings, manhattan distance used) in the cluster v2.1.0 package in R v4.0.2 (2020-06-22; R Core 
Team, The R Foundation for Statistical Computing, Vienna, Austria). Each neuron was clustered independently. 
The average silhouette width method was used to select the optimal number of clusters for each neuron. Clusters 
were graphed using the plotly v4.9.2.1 package with dependency on ggplot2. The FIBSI source code, custom 
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Python matching script, and a tutorial for using FIBSI are available on a GitHub repository (https ://githu b.com/
rmcas sidy/FIBSI _progr am).
Statistical analysis of the calcium fluctuations and sEPSCs were performed using Prism v8.2.1 (GraphPad 
Software, Inc, La Jolla, CA). The comparison between the proportion of ‘silent’ neurons in the naïve and BDNF 
treatment conditions was made using Fisher’s exact test. The Brown–Forsythe and Welch ANOVA tests and 
Games–Howell post-hoc test (for n > 50) were used to compare the effects of BDNF when the calcium fluctua-
tions from all neurons were grouped together. To control for differences in recording times, the means for each 
fluctuation parameter (amplitude, AUC, etc.) were calculated for each neuron (fluctuations < 10% the maximal 
amplitude in each neuron were omitted to remove the effects of low-amplitude noise). The amplitude and AUC 
means were normalized across all neurons to permit direct comparisons. Normality was assessed using the 
D’Agostino & Pearson omnibus test, and nonparametric comparisons between group medians were made using 
the Kruskal–Wallis test and Dunn’s post-hoc test. Two-way repeated measures ANOVAs and Sidak’s post-hoc 
tests were used to compare the pre- and post-treatment effects of octanol on the calcium fluctuations. Adjacency 
matrixes for neurons imaged together from the same organotypic culture were constructed using Pearson cor-
relation matrixes; the FIBSI-processed calcium fluctuation recordings were used as input (each recording was 
normalized on a 0 to 1 scale). Next, the mean Pearson r coefficient for each neuron within a culture was calcu-
lated using the Fisher Z transformation (steps shown in Fig. 3A). The mean Pearson r coefficients in the naïve 
and BDNF conditions were not normally distributed, so the comparison between the two was made using a 
Mann–Whitney test. Comparisons between the pre- and post-treatment effects of octanol were first made using 
a Wilcoxon matched-pairs signed rank test, and then using a two-way repeated measures ANOVA and Sidak’s 
post-hoc test. Paired t-tests were used for pharmacology experiments. Brown-Forsythe and Welch ANOVA tests 
and Games-Howell post-hoc test were used to compare the effects of BDNF on the sEPSC clusters. Statistical 
significant was set to P < 0.05 and all reported P values are two-tailed. Details for the statistical analyses can be 
found in Table 1.
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